Investing.com - Shares of Ultragenyx (NASDAQ:RARE). fell during Tuesday's after hours session in reaction to the company's report that a late-stage clinical trial for its severe muscle disease treatment failed to meet its primary endpoint.
The Phase 3 clinical trial for extended-release aceneuramic acid (Ace-ER) did not improve strength in patients with GNE Myopathy. Ultragenyx plans to discontinue further clinical development of Ace-ER.
Ultragenyx's shares fell 9% in after hours trading.